FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089334610> ?p ?o ?g. }

• W3089334610 endingPage "9688" @default.
• W3089334610 startingPage "9679" @default.
• W3089334610 abstract "The treatment (i.e. therapy and management) of chronic lymphocytic leukemia (i.e. the disease) has been improved thanks to the introduction (i.e. approval) of kinase inhibitors during the last years. PI3K is one of the most important kinases at the crossroad to the B-cell receptor and cytokine receptor which play a key role in CLL cell survival, proliferation and migration. Idelalisib is the first in class PI3Kδ inhibitor approved for the treatment of relapsed/refractory CLL in combination with rituximab. Idelalisib activity in heavily treated patients is balanced by recurrent adverse events which limit its long-term use. These limitations prompt the investigation on novel PI3K inhibitors, also targeting different protein isoforms, and alternative schedule strategies. In this regard, duvelisib is the only PI3K γ and δ inhibitor approved as single agent for relapsed CLL. In this review, we will address novel insights on PI3K structure, isoforms, regulating signaling and the most updated data of next-generation PI3K inhibitors in CLL." @default.
• W3089334610 created "2020-10-01" @default.
• W3089334610 creator A5013236194 @default.
• W3089334610 creator A5017931505 @default.
• W3089334610 creator A5018848515 @default.
• W3089334610 creator A5021204507 @default.
• W3089334610 creator A5042091314 @default.
• W3089334610 creator A5042259231 @default.
• W3089334610 creator A5045920287 @default.
• W3089334610 creator A5058373325 @default.
• W3089334610 creator A5059285761 @default.
• W3089334610 creator A5071722839 @default.
• W3089334610 creator A5078427766 @default.
• W3089334610 creator A5081202576 @default.
• W3089334610 creator A5081541878 @default.
• W3089334610 creator A5087722204 @default.
• W3089334610 date "2020-09-01" @default.
• W3089334610 modified "2023-10-18" @default.
• W3089334610 title "<p>Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia</p>" @default.
• W3089334610 cites W1481677180 @default.
• W3089334610 cites W1688381890 @default.
• W3089334610 cites W1965802234 @default.
• W3089334610 cites W1979187651 @default.
• W3089334610 cites W1992477322 @default.
• W3089334610 cites W1993192840 @default.
• W3089334610 cites W1998709192 @default.
• W3089334610 cites W2027971058 @default.
• W3089334610 cites W2038053631 @default.
• W3089334610 cites W2047401805 @default.
• W3089334610 cites W2054917860 @default.
• W3089334610 cites W2063569450 @default.
• W3089334610 cites W2077385921 @default.
• W3089334610 cites W2092014913 @default.
• W3089334610 cites W2099661341 @default.
• W3089334610 cites W2119374469 @default.
• W3089334610 cites W2119785019 @default.
• W3089334610 cites W2124186695 @default.
• W3089334610 cites W2131078883 @default.
• W3089334610 cites W2134797116 @default.
• W3089334610 cites W2135107959 @default.
• W3089334610 cites W2143327951 @default.
• W3089334610 cites W2148584975 @default.
• W3089334610 cites W2149334947 @default.
• W3089334610 cites W2167484525 @default.
• W3089334610 cites W2179878259 @default.
• W3089334610 cites W2437295469 @default.
• W3089334610 cites W2510435007 @default.
• W3089334610 cites W2545309317 @default.
• W3089334610 cites W2610856010 @default.
• W3089334610 cites W2762226752 @default.
• W3089334610 cites W2775670706 @default.
• W3089334610 cites W2782689871 @default.
• W3089334610 cites W2783291630 @default.
• W3089334610 cites W2788838674 @default.
• W3089334610 cites W2791672691 @default.
• W3089334610 cites W2792621695 @default.
• W3089334610 cites W2795923703 @default.
• W3089334610 cites W2801598494 @default.
• W3089334610 cites W2887000187 @default.
• W3089334610 cites W2890522950 @default.
• W3089334610 cites W2895287765 @default.
• W3089334610 cites W2897215992 @default.
• W3089334610 cites W2898231052 @default.
• W3089334610 cites W2903942209 @default.
• W3089334610 cites W2904653639 @default.
• W3089334610 cites W2910723008 @default.
• W3089334610 cites W2913393274 @default.
• W3089334610 cites W2917721259 @default.
• W3089334610 cites W2919429412 @default.
• W3089334610 cites W2921130376 @default.
• W3089334610 cites W2936399310 @default.
• W3089334610 cites W2943171659 @default.
• W3089334610 cites W2945654734 @default.
• W3089334610 cites W2946886038 @default.
• W3089334610 cites W2951418073 @default.
• W3089334610 cites W2964876593 @default.
• W3089334610 cites W2966533809 @default.
• W3089334610 cites W2970611430 @default.
• W3089334610 cites W2970759984 @default.
• W3089334610 cites W2976376641 @default.
• W3089334610 cites W2991368934 @default.
• W3089334610 cites W2993545373 @default.
• W3089334610 cites W3001171775 @default.
• W3089334610 cites W3010967763 @default.
• W3089334610 cites W3011178855 @default.
• W3089334610 cites W600306028 @default.
• W3089334610 cites W67399661 @default.
• W3089334610 doi "https://doi.org/10.2147/ott.s268899" @default.
• W3089334610 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7532889" @default.
• W3089334610 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33061448" @default.
• W3089334610 hasPublicationYear "2020" @default.
• W3089334610 type Work @default.
• W3089334610 sameAs 3089334610 @default.
• W3089334610 citedByCount "16" @default.
• W3089334610 countsByYear W30893346102021 @default.
• W3089334610 countsByYear W30893346102022 @default.
• W3089334610 crossrefType "journal-article" @default.
• W3089334610 hasAuthorship W3089334610A5013236194 @default.

• next